iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2014. The provided filing is an annual 10-K, not a 2013 Q4 filing. Filed September 29, 2014.
Business Context
iBio is a development-stage biotechnology company commercializing the plant-based iBioLaunch platform for producing vaccines and therapeutic proteins and the iBioModulator platform for enhancing vaccine potency and duration. The company has no marketed products and relies on licensing, collaborations, grants benefiting collaborators, equity financing, and outsourced research and development.
The principal internally advanced candidate is IBIO-CFB03 for idiopathic pulmonary fibrosis, systemic sclerosis, and potentially other fibrotic diseases. Most other candidates remain preclinical; H1N1 and H5N1 vaccine candidates completed Phase 1 trials.
Financial Results and Metrics
| Metric | FY2014 | FY2013 | Change |
|---|---|---|---|
| Revenue | $0.205 million | $1.007 million | Down $0.802 million |
| Operating expenses | $4.045 million | $7.674 million | Down $3.629 million |
| Operating loss | $3.840 million | $6.667 million | Improved $2.827 million |
| Net loss | $3.666 million | $6.198 million | Improved $2.532 million |
| Loss per share | $0.06 | $0.13 | Improved |
| Cash used in operations | $4.116 million | $4.849 million | Improved $0.733 million |
| Cash balance | $3.590 million | $4.414 million | Down $0.824 million |
| Total liabilities | $0.395 million | $4.286 million | Down $3.891 million |
| Accumulated deficit | $41.202 million | $37.536 million | Increased $3.666 million |
Revenue consisted primarily of technology services provided to FioCruz for its yellow fever vaccine program. The related research and development expense was approximately equal to revenue, producing no meaningful operating contribution. Based on reported figures, the approximate operating margin was negative 1,873% and the net margin was negative 1,788%; these ratios are not economically meaningful because revenue was minimal and the company remains development-stage.
Investing cash use was $0.259 million, primarily for intangible assets. Financing provided $3.551 million, including approximately $3.1 million from warrant exercises and $0.5 million net from a private placement. The filing does not report conventional debt; liabilities primarily consisted of accounts payable and accrued expenses.
Material Changes Versus Prior Period
- Revenue declined approximately 80% because the prior-year FioCruz technology-services activity was substantially reduced.
- Underlying research and development spending declined to approximately $1.9 million from approximately $3.4 million, excluding accounting reversals and credits.
- Reported research and development expense included credits of approximately $1.041 million from the Fraunhofer settlement and $1.007 million from the FioCruz agreement amendment.
- General and administrative expense was reported at $3.888 million, compared with $4.243 million on an adjusted basis; reported expense included a $0.700 million settlement credit and a $1.007 million receivable write-off.
- The September 2013 Fraunhofer settlement released approximately $2.9 million of liabilities, eliminated minimum annual royalty payments, reduced license-revenue royalties from 15% to 10%, and replaced certain cash obligations with a commitment to purchase at least $3 million of Fraunhofer work through December 31, 2015.
- Common shares outstanding increased from approximately 56.7 million to 65.6 million, primarily from 7.75 million warrant exercises and a 1.2 million-share private placement.
- Approximately 8.9 million warrants expired during the year, leaving approximately 8.8 million warrants outstanding at June 30, 2014.
Liquidity, Outlook, Risks, and Unusual Items
Management expects cash on hand at June 30, 2014, together with expected proceeds under the Aspire Capital agreement, to fund operations through June 30, 2015. The auditors and management reported substantial doubt about the company’s ability to continue as a going concern because of recurring losses, negative operating cash flow, limited cash, and dependence on additional financing.
After year-end, iBio entered into an agreement under which Aspire Capital committed to purchase up to $10.0 million of common stock over approximately 24 months. iBio received $0.5 million from an initial purchase and issued 681,818 commitment shares. Access to the remaining funding is uncertain, depends on market price and trading volume, and generally requires a stock price of at least $0.44 per share. Additional equity financing could materially dilute existing holders.
Management’s strategy is to obtain additional platform licenses and collaborations, advance selected candidates through preclinical and early clinical development, and rely on partners to fund later development and commercialization. No formal revenue or earnings guidance is provided. The filing states that product revenue is not expected for several years, if at all.
- Clinical, regulatory, manufacturing, and commercialization success remains unproven. Except for two completed Phase 1 vaccine programs, candidates are largely preclinical.
- The company has no approved products and no experience independently conducting late-stage trials, commercial manufacturing, sales, or marketing.
- Failure to obtain financing, licensees, or collaborators could require the company to delay programs, relinquish rights, or cease operations.
- Key programs depend on Fraunhofer, FioCruz, GE Healthcare, government agencies, foundations, and other third parties.
- Intellectual property protection, competing biologics-production technologies, regulatory changes affecting plant-based products, and clinical-trial failures are material risks.
- Unusual FY2014 results were significantly affected by nonrecurring settlement and contract-amendment reversals, including a net approximately $1.86 million positive earnings impact from the Fraunhofer settlement.
- The company had seven employees as of September 29, 2014 and outsources substantially all research and development.
Most Important Facts to Verify
- Whether Aspire Capital funding was fully accessible and how many shares were ultimately issued, including dilution from the commitment and initial purchase shares.
- Current cash burn, liquidity runway, and whether the going-concern uncertainty was subsequently resolved.
- Progress, financing, and regulatory status of IBIO-CFB03, malaria, hookworm, yellow fever, anthrax, and other pipeline programs.
- Whether FioCruz, Fraunhofer, GE Healthcare, and other collaborations generated additional license fees, milestones, royalties, or funding.
- The remaining Fraunhofer work commitment of at least $3 million through December 31, 2015 and related cash obligations.
- Current patent ownership, expiration dates, pending applications, and freedom-to-operate risks.
- Fully diluted share count, including approximately 8.5 million options, 8.8 million warrants, and additional shares available under equity plans and financing agreements.